Physician profile
Aiyub Patel
NPI 1215153077
$6,754.38
in general payments reported to CMS, 2019-2025
34 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 85% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $175 · 2021: $327 · 2022: $994 · 2023: $1,347 · 2024: $1,498 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.94 |
| Education | $128.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,945.38 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Jazz Pharmaceuticals INC. | $1,053.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.57 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Harmony Biosciences LLC | $534.89 | 2021-2025 | Wakix |
| Glaxosmithkline, LLC. | $414.11 | 2019-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $220.45 | 2019-2024 | Yupelri |
| Insmed, INC. | $219.34 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $217.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $183.94 | 2019-2025 | Dupixent |
| Intuitive Surgical, INC. | $178.13 | 2021-2023 | Da Vinci Surgical System |
| Verona Pharma, INC. | $122.00 | 2025 | Ohtuvayre |
| Philips North America LLC | $118.91 | 2019-2024 | (Ak6) Vest Therapy |
| Electromed, INC. | $117.12 | 2022-2024 | Smartvest |
| Grifols USA, LLC | $116.43 | 2022-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $83.77 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $80.20 | 2025 | Yupelri |
| Shionogi INC | $46.76 | 2024 | Fetroja |
| Axsome Therapeutics, INC. | $43.81 | 2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $41.78 | 2021-2022 | |
| Advanced Respiratory, INC | $41.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.89 | 2023-2024 | Glassia |
| Amgen INC. | $32.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $30.58 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $29.96 | 2023 | |
| La Jolla Pharmaceutical Company | $23.97 | 2023 | Giapreza |
| Boston Scientific Corporation | $18.74 | 2022 | |
| Pulmonx Corporation | $18.06 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.66 | 2019 | |
| Veran Medical Technologies, INC. | $16.63 | 2020 | |
| Teleflex LLC | $15.78 | 2025 | Manta |
| Circassia INC. | $15.73 | 2019 | |
| Inogen, INC. | $14.82 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.76 | 2021 | |
| Breathe Technologies, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aiyub Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.